This new partnership follows the relaunch of FENO-SAMBUCUS™ 30 earlier this year. The high-strength, excipient-free extract was identified by this partner as an innovation unique in the market. It compelled their desire to sell the product and drive new business through the immune category. The partner is a global nutraceutical player based in Canada and a subsidiary of a multinational group with extensive reach across multiple channels. With a strong sales force and premium marketing capabilities, the new partner brings capability to scale sales to a new level.

“Our new partner helped us understand that Eevia has a unique category of high-strength extracts which provides multiple operational benefits for manufacturers of consumer dosages. Being excipient free, it also reduces the chance for adulteration and imposters. This partnership validates the new strategy we decided in 2024 on many levels,” says Erik Eide, Commercial Director of Eevia Health.

FENO-SAMBUCUS™ 30 has twice the amount of key bioactives compared to any other elderberry extract on the market. It is produced from European Elderberries (Sambucus nigra) with 30% anthocyanins and 50% total polyphenols—including unique high levels of proanthocyanidins. Compared to the common compendial extract that has 15% anthocyanins, the double-potency reduces the dosage volume required in supplements and unlocks new formulations with the potential to offer lower cost per dose and additional quality improvements.

FENO-SAMBUCUS™ 30 is manufactured at Eevia’s Finnish green-chemistry manufacturing facility, with solvent-free extraction and advanced chromatographic purification. The product has the lowest carbon footprints in the industry and is virtually sugar-free—setting a new benchmark for purity, and sustainability in the category. Recent in vitro testing confirmed the product’s superior bioactivity across 138 human biomarkers, validating its effectiveness in supporting immune health and more.

This initial order of KEUR 70 marks the start of the partnership and partnering with such powerfiul sales organization is a brilliant inflection point in the execution of Eevia’s strategy to expand globally through high-impact plant-based and science-backed health-solutions.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga mushroom, and pine bark, are wild harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden (Ticker EEVIA).

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.